Biogen says it's cutting about 11 percent of its workforce and ending some development programs in a restructuring aimed to save $250 million a year.» Read More
“Mad Money” host Jim Cramer says he’s being kind with his criticism of this popular ratings and reviews company.
Jim Cramer thinks leadership is lacking, which prompted the market to get crushed Friday.
Dollar strength, weak oil weigh on earnings.
U.S. stocks closed about 1 percent lower, despite surprisingly strong Amazon earnings, as signs of slower global growth weighed on sentiment.
Biogen shares sank after it lowered its 2015 forecast on slower-than-anticipated growth of its multiple sclerosis blockbuster Tecfidera.
*Tecfidera U.S. growth to be flat for rest of 2015. July 24- Biogen Inc more than halved its sales growth forecast for 2015, saying it expects demand for its flagship multiple sclerosis drug, Tecfidera, to continue slowing this year in the United States. Biogen's stock fell as much as 18.8 percent to a seven-month low, wiping out about $17 billion of its value, after the...
CNBC's Meg Tirrell reports on Biogen's sales growth as the company misses sales estimates.
Jim Cramer explains why he is watching shares of Biogen after the company lowered its guidance
U.S. stock futures pointed to a slight rebound following a stronger-than-expected earnings report from online retailer Amazon.
Some of the names on the move ahead of the open.
July 24- Sales of Biogen Inc's roster of multiple sclerosis drugs failed to meet analysts' expectation, prompting the company to slash its full-year profit and sales forecast. Tecfidera's sales were $833 million in the second quarter ended June 30, well below Wall Street's estimate of about $933 million, according to Evercore ISI. Sales of Biogen's injectable...
July 24- Biogen Inc reported a 30 percent rise in quarterly profit, driven by strong sales of its top-selling oral multiple sclerosis drug, Tecfidera. Net profit attributable to Biogen rose to $927.3 million, or $3.93 per share, in the second quarter ended June 30, from $714.5 million, or $3.01 per share, a year earlier. The U.S. biotechnology company's revenue rose...
U.S. stock futures pointed to a rebound for Wall Street shares Friday, following a stronger-than-expected earnings report from online retailer Amazon.
Stocks could get a boost Friday from Amazon's strong earnings report, which comes as some key companies are clearly stumbling over the already lowered bar for earnings.
*Nidec jumps 10 pct on strong April-June results. *Komatsu, Hitachi Construction Machinery fall before Caterpillar's earnings. TOKYO, July 23- Japan's Nikkei share average rose on Thursday morning on domestic earnings optimism after electric motor maker Nidec Corp reported strong quarterly results.
Biogen's Alzheimer's drug showed promise in its latest study, Chief Medical Officer Alfred Sandrock said.
CNBC's Meg Tirrell reports on the highly-anticipated data on Biogen's new Alzheimer drug.
Medicines in development at Biogen and Eli Lilly could be the first to slow the cognitive declines brought by Alzheimer’s disease. How do they work?
Biogen is looking to settle on one key thing: the perfect dose for its experimental Alzheimer's drug.
In a note to clients, Morgan Stanley recommended investors buy a group of stocks it expects to rally on earnings.